ChromaDex to Present at the 11th Annual LD Micro Main Event
November 28 2018 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief
Executive Officer, Rob Fried, Co-Founder & Executive Chairman,
Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present
at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard
Hotel in Los Angeles, CA.
The ChromaDex management team is scheduled to present on Wed.,
Dec. 5, 2018, at 4:30 p.m. PST. ChromaDex management will
also attend one-on-one meetings with institutional investors
throughout the day.
The LD Micro Main Event is the largest independent conference
for small/micro-cap companies and will feature 250 companies
presenting to an audience of over 1,200 attendees.
About ChromaDex:
ChromaDex Corp. is an integrated, global
nutraceutical company devoted to improving the way people age.
ChromaDex scientists partner with leading universities and research
institutions worldwide to uncover the full potential of NAD and
identify and develop novel, science-based ingredients. Its flagship
ingredient, NIAGEN® nicotinamide riboside, sold directly to
consumers as TRU NIAGEN®, is backed with clinical and scientific
research, as well as extensive IP protection. TRU NIAGEN® is
helping the world AGE BETTER®. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space.
What started out as a newsletter highlighting unique companies
has transformed into several influential events annually
(Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi)
to exclusively provide intraday information on the entire sector.
LD will continue to provide valuable tools for the benefit of
everyone in the small and micro-cap universe. For those interested
in attending, please contact David Scher at david@ldmicro.com or
visit www.ldmicro.com for more information.
Forward-Looking Statements:
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of
1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 30, 2017, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a portion of
the grant funding as a collaborator for the study.
ChromaDex Investor Relations Contact: Brianna
Gerber, Senior Director of FP&A and Investor Relations
949-344-3782 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024